Introduction {#acn3274-sec-0005}
============

Accumulation of *β*‐amyloid (A*β*) containing neuritic plaques is one of the core neuropathological characteristics of Alzheimer\'s disease (AD). A*β* is produced from a transmembrane A*β* precursor protein (APP), when the latter is sequentially cleaved by *β*‐ and *γ*‐secretase.[1](#acn3274-bib-0001){ref-type="ref"} Cleavage of APP by *γ*‐secretase generates a number of A*β* isoforms[2](#acn3274-bib-0002){ref-type="ref"} among which A*β*42, a 42 amino acid‐long peptide, has the highest propensity for aggregation[3](#acn3274-bib-0003){ref-type="ref"}, [4](#acn3274-bib-0004){ref-type="ref"} and appears to be the predominant species in neuritic plaques.[5](#acn3274-bib-0005){ref-type="ref"} A*β*42 in the cerebrospinal fluid (CSF) is an established biomarker of AD, and is used both in clinical trials and increasingly in clinical practice.[6](#acn3274-bib-0006){ref-type="ref"} Decreased CSF A*β*42 have been consistently found in the CSF of AD patients allowing discrimination from healthy aged controls with specificity and sensitivity between 80% and 90%.[7](#acn3274-bib-0007){ref-type="ref"} Postmortem studies have demonstrated inverse correlations between CSF A*β*42 and neuritic plaque burden suggesting that low levels of A*β*42 in CSF are caused by its deposition in the brain parenchyma.[8](#acn3274-bib-0008){ref-type="ref"}, [9](#acn3274-bib-0009){ref-type="ref"} While CSF analysis provides concentrations of soluble A*β*42, fibrillar amyloid plaques may be directly visualized using amyloid positron emission tomography (PET) imaging. A significant proportion of healthy individuals and patients with mild cognitive impairment (MCI) show discordant CSF A*β*42 and amyloid PET status, indicating that new algorithms for the use of CSF A*β*42 may improve its capacity to detect early amyloid pathology.[10](#acn3274-bib-0010){ref-type="ref"}, [11](#acn3274-bib-0011){ref-type="ref"} At the same time, reduced CSF levels of A*β*42 have also been found in non‐AD dementias such as vascular dementia (VaD), Parkinson\'s disease with dementia (PDD), and dementia with Lewy bodies (DLB).[12](#acn3274-bib-0012){ref-type="ref"} In these circumstances, the clinical utility of A*β*42 as AD biomarker is limited.

Besides A*β*42, several shorter isoforms of A*β* are present in CSF including A*β*40 and A*β*38.[13](#acn3274-bib-0013){ref-type="ref"} Some papers suggest that the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios might improve discrimination of AD dementia from frontotemporal dementia (FTD) and/or DLB[14](#acn3274-bib-0014){ref-type="ref"}, [15](#acn3274-bib-0015){ref-type="ref"}, [16](#acn3274-bib-0016){ref-type="ref"} and improve prediction of AD in subjects with MCI compared to CSF A*β*42 alone.[17](#acn3274-bib-0017){ref-type="ref"} However, the A*β*42/A*β*40 and A*β*42/A*β*38 ratios have not yet been validated in large clinical cohorts and not against amyloid PET imaging. Further, the mechanisms underlying the improved diagnostic performance of A*β*42/A*β*40 and A*β*42/A*β*38 ratios are at present unknown. It is possible that these ratios may correct for interindividual variability in the overall A*β* production, since A*β*38 and A*β*40 are expected to increase due to higher overall A*β* production, but not decrease (in contrast to A*β*42) as a result of AD pathology. It is also possible that other non‐AD‐specific subcortical changes may affect global levels of all the three A*β* isoforms in the brain.[18](#acn3274-bib-0018){ref-type="ref"} Therefore, we evaluated whether the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios would better reflect AD‐type pathology compared with CSF A*β*42 alone. This study comprised three different cohorts with 1182 individuals in total where we: (1) determined if the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios measured using three different immunoassays showed improved agreement with amyloid (^18^F‐flutemetamol) PET imaging compared with CSF A*β*42; (2) investigated associations between CSF A*β*42, the A*β*42/A*β*40, and A*β*42/A*β*38 ratios with magnetic resonance imaging (MRI) measures of hippocampal volume, lateral ventricular volume, and white matter lesions; (3) studied if the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios were more selective biomarkers for differentiating AD from other neurodegenerative dementias including VaD, DLB, and PDD.

Materials and Methods {#acn3274-sec-0006}
=====================

Study populations {#acn3274-sec-0007}
-----------------

The study was approved by the Regional Ethics Committee in Lund, Sweden, and the patients and/or their relatives gave their informed consent (for research).

### Cohort‐1 {#acn3274-sec-0008}

The study population stemmed from the prospective and longitudinal Swedish BioFINDER study (further information available at: [www.biofinder.se](http://www.biofinder.se)). The included cases (*n* = 215) consisted of patients with mild cognitive complaints enrolled consecutively at three memory outpatient clinics in Sweden, who all had undergone ^18^F‐flutemetamol PET. The patients were referred for assessment of their cognitive complaints and were included between 2010 and 2014. They were thoroughly assessed for their cognitive complaints by physicians with special interest in dementia disorders. The inclusion criteria were: (1) cognitive symptoms; (2) not fulfilling the criteria for dementia; (3) a Mini‐Mental State Examination (MMSE) score of 24--30 points[19](#acn3274-bib-0019){ref-type="ref"}; (4) age 60--80 years; and (5) fluent in Swedish. The exclusion criteria were: (1) cognitive impairment that without doubt could be explained by another condition (other than prodromal dementias); (2) severe somatic disease; and (3) refusing lumbar puncture or neuropsychological investigation. These criteria resulted in a clinically relevant population where 47% were classified as subjective cognitive decline, 40% as amnestic MCI, and 11% as non‐amnestic MCI. The classification was based on a neuropsychological battery assessing the cognitive domains of verbal ability, visuospatial construction, episodic memory, and executive functions and the clinical assessment by a senior neuropsychologist as described in Data S1. The characteristics of cohort‐1 are given in Table S1.

### Cohort‐2 {#acn3274-sec-0009}

This study was performed at the Memory Clinic of Skåne University Hospital in Malmö. CSF samples were obtained from 53 cognitively healthy elderly subjects and from patients with stable MCI (sMCI, *n* = 62), MCI that subsequently developed AD dementia (MCI‐AD, *n* = 35), AD dementia (*n* = 75), subcortical VaD (*n* = 34), PDD or DLB (*n* = 47) as well as with FTD (*n* = 33). Diagnostic criteria in cohort‐2 are described in Data S1. The control population consisted of healthy elderly volunteers, who were recruited in the city of Malmö, Sweden. Inclusion criteria were (1) absence of memory complaints or any other cognitive symptoms; (2) preservation of general cognitive functioning; and (3) no active neurological or psychiatric disease. The characteristics of cohort‐2 are given in Table S2.

### Cohort‐3 {#acn3274-sec-0010}

The study population stemmed from the prospective and longitudinal Swedish BioFINDER study ([www.biofinder.se](http://www.biofinder.se)). We included healthy elderly controls (*n* = 328), cases with AD (*n* = 137), cases with PD (*n* = 128), and cases with PDD or DLB (*n* = 35). The same diagnostic criteria were used for AD, PD, and DLB as in cohort‐2. Subjects were eligible for inclusion in the cognitively healthy elderly cohort of the Swedish BioFINDER study if they (1) were aged ≥60 years old; (2) scored 28--30 points on MMSE; (3) did not suffer from any subjective cognitive impairment; and (4) were fluent in Swedish. Exclusion criteria included presence of significant neurologic disease (e.g., stroke, Parkinson\'s disease, multiple sclerosis), severe psychiatric disease (e.g., severe depression or psychotic syndromes), dementia or MCI. The characteristics of cohort‐3 are given in Table S3.

CSF sampling and analysis {#acn3274-sec-0011}
-------------------------

The procedure and analysis of the CSF followed the Alzheimer\'s Association Flow Chart for CSF biomarkers.[7](#acn3274-bib-0007){ref-type="ref"} Lumbar CSF samples were collected at the three centers and analyzed according to a standardized protocol.[7](#acn3274-bib-0007){ref-type="ref"}, [20](#acn3274-bib-0020){ref-type="ref"} CSF A*β*42, A*β*40, and A*β*38 were analyzed by Euroimmun (EI) (EUROIMMUN AG, Lübeck, Germany) and Meso Scale Discovery (MSD) (Rockville, MD) immunoassays. CSF A*β*40 and A*β*42 were also analyzed using Quanterix (Quanterix, Lexington, MA) immunoassay. The EI assays were used to measure CSF A*β* (1--42, 1--40, and 1--38) in all three cohorts. In addition, in cohort‐1, all the CSF samples were analyzed with MSD kit (specific for A*β*N‐42, A*β*N‐40 and A*β*N‐38) and 70 CSF samples were analyzed using Quanterix kit (specific for A*β*N‐42 and A*β*N‐40).

Brain imaging {#acn3274-sec-0012}
-------------

### ^18^F‐flutemetamol PET in cohort 1 {#acn3274-sec-0013}

Cerebral A*β* deposition was visualized with the PET tracer ^18^F‐flutemetamol (approved by the Food and Drug Administration, and the European Medical Agency). PET/CT scanning of the brain was conducted at two sites using the same type of scanner (Gemini, Philips Healthcare, Best, the Netherlands). Sum images from 90--110 min postinjection were analyzed using the software NeuroMarQ (GE Healthcare, Cleveland, OH). A volume of interest (VOI) template was applied for the following nine bilateral regions: prefrontal, parietal, lateral temporal, medial temporal, sensorimotor, occipital, anterior cingulate, posterior cingulate/precuneus, and a global neocortical composite region.[21](#acn3274-bib-0021){ref-type="ref"} The standardized uptake value ratio (SUVR) was defined as the uptake in a VOI normalized for the cerebellar cortex uptake.

### Magnetic resonance imaging in cohort 1 {#acn3274-sec-0014}

All patients were examined using a single‐3T MR scanner (Trio; Siemens, Munich, Germany). The volumes of hippocampus and the lateral ventricles were analyzed with Volbrain 1.0.[22](#acn3274-bib-0022){ref-type="ref"} Quality control of the segmentation of subcortical structures on MRI images was done by visual inspection of all included subjects. Automated segmentation of white matter lesions was performed using the Lesion Segmentation Tool (LST) implemented in SPM8 (<http://www.applied-statistics.de/lst.html>); this generated a total white matter lesion volume (mL) for each individual. Prior to this, manual segmentation for reference of white matter lesions was performed on FLAIR images coregistered to the native MPRAGE in four MCI patients, with the segmented volume ranging from 0.5 to 106.3 mL; the resulting optimal *κ* based on the Dice coefficient was 0.4[23](#acn3274-bib-0023){ref-type="ref"} and was used in the subsequent automated segmentation for all participants. The protocol comprised axial T2 FLAIR imaging (IPAT factor = 0, TR/TE/TI = 9000/89/2500 msec, 27 slices, reconstructed image resolution 0.7 × 0.7 × 5.2 mm^3^, acquisition time 4.14 min), and a coronal MPRAGE sequence (IPAT factor = 0, TR/TE/flip angle = 1950/3 msec/9°, 180 slices, slice thickness 1.2 mm, image resolution 1 × 1 × 1.2 mm^3^, acquisition time 6.02 min).

### Computed tomography and magnetic resonance imaging in cohort 2 {#acn3274-sec-0015}

In cohort 2, 310 cases underwent CT (*n* = 266) and MRI (*n* = 44) examinations. Using axial CT or MRI images, Evan\'s index was calculated by dividing the distance between the frontal horns of the lateral ventricles at the level of foramen Monroi with the maximal internal diameter of the skull in the same plane.

Statistical analyses {#acn3274-sec-0016}
--------------------

SPSS (IBM, Armonk, NY) and R version 3.1.2[24](#acn3274-bib-0024){ref-type="ref"} were used for statistical analysis. White matter lesion volumes were skewed and therefore ln‐transformed before statistical analysis. Linear regressions were used to investigate associations between a continuous‐dependent variable and continuous or categorical independent variables. For groupwise comparisons, we used univariate general linear models. Univariate logistic regression models were employed to predict a dichotomized categorical variable from categorical and continuous independent variables. To control the confounding factors, age and sex were included in all the regression models. 95% confidence intervals for *β*‐coefficients from linear regression models were estimated by a bootstrap procedure (*n* = 1000). To test if CSF biomarkers had different associations with different MRI measures (hippocampal volume, lateral ventricular volume and white matter lesions volume), we compared MRI measures pairwise and used linear mixed‐effects models after concatenating two (standardized) response vectors (the MRI measures being compared, for example hippocampus and lateral ventricle). We included an interaction between a factor for MRI measure and CSF biomarker, as a predictor. When this interaction was significant, it indicated that the tested biomarker had different statistical effects on the two included MRI measures. The models also included age, sex, and both main effects as predictors. All models included a random intercept and a random term for MRI measure. Area under the curve (AUC) of two receiver operating characteristic (ROC) curves were compared with DeLong test.[25](#acn3274-bib-0025){ref-type="ref"} Youden\'s J index was calculated as sensitivity + specificity − 1 for each of the points of the ROC curve. The optimal cutoff was defined as corresponding to the highest J index. *P* \< 0.05 was considered statistically significant.

Results {#acn3274-sec-0017}
=======

CSF A*β* isoforms and amyloid PET imaging (cohort‐1) {#acn3274-sec-0018}
----------------------------------------------------

To determine how well different CSF A*β* isoforms could distinguish patients in cohort‐1 with abnormal (PET^+^) and normal (PET^−^) amyloid PET, we compared the concordance between ^18^F‐flutemetamol imaging and CSF A*β*42, the A*β*42/A*β*40, and A*β*42/A*β*38 ratios measured with EI, MSD, and Quanterix immunassays. We have recently established that composite SUVR of ^18^F‐flutemetamol data show bimodal distribution and could be separated in two populations using mixture modeling analysis that generated the cutoff \>1.42 SUVR for abnormally increased A*β* deposition.[20](#acn3274-bib-0020){ref-type="ref"} When using CSF values derived from the EI immunoassay, we found that A*β*42 outperformed A*β*40 and A*β*38 in terms of accuracy, specificity, and sensitivity (Table [1](#acn3274-tbl-0001){ref-type="table-wrap"}). When comparing AUCs of individual ROC curves, the A*β*42/A*β*40 and A*β*42/A*β*38 ratios performed significantly better than A*β*42 alone (*P* = 0.008 and 0.007; Table [1](#acn3274-tbl-0001){ref-type="table-wrap"}, Fig. [1](#acn3274-fig-0001){ref-type="fig"}A) whereas there was no difference between the A*β*42/A*β*40 and the A*β*42/A*β*38 ratios (*P* = 0.242). The results were the similar when A*β* isoforms were measured using the MSD and the Quanterix immunoassay (Table [1](#acn3274-tbl-0001){ref-type="table-wrap"}, Fig. [1](#acn3274-fig-0001){ref-type="fig"}B and C).

###### 

ROC analysis of CSF A*β*42, A*β*40, A*β*38, the A*β*42/A*β*40, and A*β*42/A*β*38 ratios for detecting abnormal (≥1.42) and normal (\<1.42) amyloid PET

                  AUC                                                                                Cutoff           Youden\'s J index   Sensitivity   Specificity
  --------------- ---------------------------------------------------------------------------------- ---------------- ------------------- ------------- -------------
  Euroimmun                                                                                                                                             
  A*β*42          0.894, 95% CI = 0.850--0.937, *P* \< 0.001                                         \<507.5 pg/mL    0.665               0.832         0.833
  A*β*40          0.556, 95% CI = 0.480--0.633, *P* = 0.153                                          \>3830 pg/mL     0.115               0.722         0.393
  A*β*38          0.569, 95% CI = 0.492--0.646, *P* = 0.081                                          \>1662 pg/mL     0.191               0.630         0.561
  A*β*42/A*β*40   0.954[a](#acn3274-note-0003){ref-type="fn"}, 95% CI = 0.923--0.986, *P* \< 0.001   \<0.10           0.852               0.972         0.880
  A*β*42/A*β*38   0.943[b](#acn3274-note-0003){ref-type="fn"}, 95% CI = 0.911--0.975, *P* \< 0.001   \<0.29           0.814               0.925         0.889
  MSD                                                                                                                                                   
  A*β*42          0.916, 95% CI = 0.876--0.956, *P* \< 0.001                                         \<495.9 pg/mL    0.739               0.850         0.889
  A*β*40          0.559, 95% CI = 0.483--0.636, *P* = 0.132                                          \>6117 pg/mL     0.145               0.500         0.645
  A*β*38          0.566, 95% CI = 0.490--0.643, *P* = 0.093                                          \>3121 pg/mL     0.136               0.435         0.701
  A*β*42/A*β*40   0.975[c](#acn3274-note-0003){ref-type="fn"}, 95% CI = 0.952--0.998, *P* \< 0.001   \<0.09           0.907               0.953         0.954
  A*β*42/A*β*38   0.964[d](#acn3274-note-0003){ref-type="fn"}, 95% CI = 0.935--0.992, *P* \< 0.001   \<0.17           0.889               0.972         0.917
  Quanterix                                                                                                                                             
  A*β*42          0.810, 95% CI = 0.707--0.913, *P* \< 0.001                                         \<1742 pg/mL     0.508               0.733         0.775
  A*β*40          0.590, 95% CI = 0.450--0.730, *P* = 0.200                                          \>11,328 pg/mL   0.317               0.750         0.567
  A*β*42/A*β*40   0.912[e](#acn3274-note-0003){ref-type="fn"}, 95% CI = 0.834--0.991, *P* \< 0.001   \<0.16           0.800               0.900         0.900

ROC, receiver operating characteristic; CSF, cerebrospinal fluid; PET, positron emission tomography; AUC, area under the curve; MSD, Meso Scale Discovery.

^a^ *P*=0.008, ^b^ *P*=0.007, ^c^ *P*\<0.001, ^d^ *P*=0.007 and ^e^ *P*=0.002 when comparing to A*β*42 AUC.
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![ROC curves of CSF A*β*42 and the A*β*42/A*β*40 and A*β*42/A*β*38 ratios for discriminating abnormal (≥1.42) and normal (\<1.42) amyloid PET. A*β* isoforms were measured in 108 PET‐positive and 107 PET‐negative cases using the Euroimmun (A) and MSD (B) immunoassays, and in 40 PET‐positive and 30 PET‐negative cases using the Quanterix immunoassay (C); \*\**P* \< 0.01, \*\*\**P* \< 0.001 when comparing to A*β*42 AUC. ROC, receiver operating characteristic; CSF, cerebrospinal fluid; PET, positron emission tomography; MSD, Meso Scale Discovery; AUC, area under the curve.](ACN3-3-154-g001){#acn3274-fig-0001}

Based on the optimal cutoff points corresponding to the highest Youden\'s J indices (Table [1](#acn3274-tbl-0001){ref-type="table-wrap"}), we dichotomized CSF A*β* variables (derived from the EI assay) into abnormal (A*β* ^+^) and normal (A*β* ^−^) values. Logistic regression was used to predict probability of abnormal or normal PET composite score with dichotomized A*β* variables as predictors. Overall prediction success rate for the model including A*β*42 was 83% (odds ratio 25, 95% CI 12--51, *P* \< 0.001). Prediction success rate increased to 93% for the A*β*42/A*β*40 ratio (odds ratio 253, 95% CI 70--916, *P* \< 0.001) and 91% for the A*β*42/A*β*38 ratio (odds ratio 99, 95% CI 39--253, *P* \< 0.001). The results were similar when adjusting for confounding effect of global cognition (MMSE score), *APOE* genotype, and education (data not shown). Cohen\'s *κ* for A*β*42, the A*β*42/A*β*40, and A*β*42/A*β*38 ratios were 66%, 85%, and 81%, respectively which suggests very good agreement between amyloid PET data and the CSF A*β* ratios[26](#acn3274-bib-0026){ref-type="ref"} (Fig. [2](#acn3274-fig-0002){ref-type="fig"}A--C). Very comparable results were obtained using the MSD and Quanterix immunoassays (Fig. [2](#acn3274-fig-0002){ref-type="fig"}D--F, Table S4, Fig. S1).

![Scatterplots of CSF A*β*42 and the A*β*42/A*β*40 and A*β*42/A*β*38 ratios and amyloid PET SUVR values. (A--C) depict CSF values derived from the Euroimmun immunoassay. Horizontal lines represent optimal cutoffs for A*β*42 (A, cut off 507.5 pg/mL, 83% was identified identically with CSF and PET), A*β*42/A*β*40 (B, cut off 0.10, 93% was identified identically with CSF and PET) and A*β*42/A*β*38 (C, cut off 0.29, 91% was identified identically with CSF and PET) corresponding to the highest Youden\'s J indices. (D and E) depict CSF values derived from the MSD immunoassay. Horizontal lines represent optimal cutoffs for A*β*42 (D, cut off 495.9 pg/mL, 87% was identified identically with CSF and PET), A*β*42/A*β*40 (E, cut off 0.09, 95% was identified identically with CSF and PET) and A*β*42/A*β*38 (F, cut off 0.17, 93% was identified identically with CSF and PET). The PET cutoff 1.42 has been defined previously.[20](#acn3274-bib-0020){ref-type="ref"} CSF, cerebrospinal fluid; PET, positron emission tomography; SUVR, standardized uptake value ratio.](ACN3-3-154-g002){#acn3274-fig-0002}

Additional analyses were performed to better understand the effects of using the CSF A*β*42/A*β*40 ratio instead of CSF A*β*42 measurements alone. First, we plotted combinations of CSF A*β*42 and CSF A*β*42/A*β*40 as a function of amyloid PET (using standardized CSF measures; EI Fig. [3](#acn3274-fig-0003){ref-type="fig"}A and MSD Fig. [3](#acn3274-fig-0003){ref-type="fig"}C). This suggested that the CSF A*β*42/A*β*40 ratio had different effects in subjects with low versus high amyloid PET levels. Specifically, in subjects with low amyloid PET levels, the CSF A*β*42/A*β*40 ratio primarily adjusted low CSF A*β*42 toward higher (more normal) levels, and in subjects with intermediate amyloid PET levels, the CSF A*β*42/A*β*40 ratio primarily adjusted high CSF A*β*42 toward lower (more pathological) levels. This corresponded to a different classification of pathological versus normal amyloid status when using the CSF A*β*42/A*β*40 ratio. For the MSD assays (Fig. [3](#acn3274-fig-0003){ref-type="fig"}D), 15 subjects who were classified as pathological by CSF A*β*42 were reclassified as normal by the CSF A*β*42/A*β*40 ratio (12 \[80%\] of these had normal amyloid PET levels), and eight subjects who were classified as normal by CSF A*β*42 were reclassified as pathological by the CSF A*β*42/A*β*40 ratio (all \[100%\] of these had pathological amyloid PET levels). The results were very similar for the EI assay (Fig. [3](#acn3274-fig-0003){ref-type="fig"}B).

![Effects of using the CSF A*β*42/A*β*40 ratio instead of the CSF A*β*42 measurement alone. The CSF values derived from the EI assay are given in (A and B) and values from the MSD assay are given in (C and D). (A and C) depict the differences between standardized CSF A*β*42/A*β*40 ratio and CSF A*β*42 (*y*‐axis) as a function of amyloid PET (*x*‐axis). Cases where the ratio was lower than CSF A*β*42 alone are indicated by solid gray lines and cases where the ratio was higher than CSF A*β*42 alone are indicated by dashed red lines. A local regression line suggested that the ratio adjusted the results upwards mainly in the low amyloid PET range and downwards mainly in the medium‐high amyloid PET range. (B and D) depict the change in classification of subjects when using the CSF A*β*42/A*β*40 ratio instead of CSF A*β*42 alone (based on cutoffs presented in Table [1](#acn3274-tbl-0001){ref-type="table-wrap"}). Green and red circles indicate that subjects were consistently classified as normal or pathological, respectively, when using CSF A*β*42 alone or the ratio. Blue dots indicate that subjects changed classification from pathological to normal when using the ratio, and orange dots indicate that subjects changed classification from normal to pathological when using the ratio. CSF, cerebrospinal fluid; EI, Euroimmun; MSD, Meso Scale Discovery; PET, positron emission tomography.](ACN3-3-154-g003){#acn3274-fig-0003}

CSF A*β* isoforms and MRI measures (cohort‐1) {#acn3274-sec-0019}
---------------------------------------------

Next, we wanted to understand why the ratios perform better than A*β*42 alone. We hypothesized that the ratios better reflect AD‐type pathology (such as hippocampal atrophy), but are not associated with imaging features not specific for AD such as white matter lesions and enlarged lateral ventricles. We found that lower CSF A*β*42, A*β*42/A*β*40, and A*β*42/A*β*38 ratios were associated with smaller hippocampal volumes (Table [2](#acn3274-tbl-0002){ref-type="table-wrap"}). No such correlations were observed for either A*β*40 or A*β*38. Further, lower levels of A*β*42, A*β*40, and A*β*38, but not the A*β*42/A*β*40 or A*β*42/A*β*38 ratios, were all associated with larger volumes of the lateral ventricles and white matter lesions (Table [2](#acn3274-tbl-0002){ref-type="table-wrap"}). When directly comparing the associations between CSF biomarkers and different MRI measures using linear mixed‐effects models, we found that CSF A*β*42, A*β*42/A*β*40, and A*β*42/A*β*38 ratios had significantly greater associations with hippocampal volume than with ventricular volume and white matter lesions (data not shown).

###### 

Associations between CSF biomarkers and MRI measures including hippocampal volume, lateral ventricular volume and white matter lesions volume

                  Hippocampal volume                                         Lateral ventricular volume                                    White matter lesion volume
  --------------- ---------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  A*β*38          *β* = −0.056, *P* = 0.416 (−0.193, 0.081)                  ***β*** **= −0.433,** ***P*** **\< 0.001 (−0.525, −0.341)**   ***β*** **= −0.256,** ***P*** **\< 0.001 (−0.358, −0.154)**
  A*β*40          *β* = −0.044, *P* = 0.533 (−0.191, 0.103)                  ***β*** **= −0.381,** ***P*** **\< 0.001 (−0.475, −0.288)**   ***β*** **= −0.273,** ***P*** **\< 0.001 (−0.382, −0.163)**
  A*β*42          ***β*** **= 0.177,** ***P*** **= 0.009 (0.061, 0.293)**    ***β*** **= −0.186,** ***P*** **= 0.004 (−0.285, −0.088)**    ***β*** **= −0.170,** ***P*** **= 0.010 (−0.308, −0.032)**
  A*β*42/A*β*40   ***β*** **= 0.234,** ***P*** **\< 0.001 (0.117, 0.350)**   *β* = 0.127, *P* = 0.060 (0.017, 0.237)                       *β* = 0.052, *P* = 0.429 (−0.072, −0.177)
  A*β*42/A*β*38   ***β*** **= 0.226,** ***P*** **= 0.001 (0.107, 0.344)**    *β* = 0.037, *P* = 0.574 (−0.072, 0.146)                      *β* = −0.037, *P* = 0.568 (−0.180, 0.105)

Data are derived from linear regression models adjusting age and sex. *β*, standardized coefficient; data are presented as *β* (95% confidence interval); significant results are shown in bold. CSF, cerebrospinal fluid; MRI, magnetic resonance imaging.
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CSF A*β* isoforms in AD and non‐AD dementia (cohort‐2) {#acn3274-sec-0020}
------------------------------------------------------

Now, we wanted to establish whether CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios are significantly better than CSF A*β*42 alone to distinguish patients with AD dementia from those with non‐AD dementias, including non‐AD patients with subcortical pathology. To this end, we measured CSF levels of A*β*42, A*β*40, and A*β*38 in cohort‐2 that included healthy controls, patients with stable MCI, MCI who later developed AD, AD dementia, PDD/DLB, VaD, and FTD. Majority of individuals in cohort‐2 (310 out of 339) underwent CT or MRI (but not PET). CSF A*β*42 levels did not differ between AD and PDD/DLB, but were decreased in AD compared to controls, sMCI, VaD, and FTD (Fig. [4](#acn3274-fig-0004){ref-type="fig"}A). However, the A*β*42/A*β*40 and A*β*42/A*β*38 ratios were lower in AD compared to all the other diagnostic groups (Fig. [4](#acn3274-fig-0004){ref-type="fig"}D and E). A*β*40 and A*β*38 were lower in PDD/DLB and VaD groups compared to AD group (Fig. [4](#acn3274-fig-0004){ref-type="fig"}B and C). Differences between AD and other non‐AD dementias were more pronounced for A*β*42/A*β*40 and A*β*42/A*β*38 than for A*β*42 alone (Fig. [4](#acn3274-fig-0004){ref-type="fig"}A, D and E, Table S2).

![A*β*42, A*β*40, A*β*38, A*β*42/A*β*40 ratio, and A*β*42/A*β*38 ratio in the CSF of patients with different forms of dementia, sMCI and healthy controls. (A--E) A*β*42, A*β*40, A*β*38, A*β*42/A*β*40 ratio, and A*β*42/A*β*38 ratio in the CSF of healthy controls (*n* = 53) and patients with sMCI (*n* = 62 for A*β*42, A*β*40; *n* = 61 for A*β*38), AD (*n* = 110), PDD/DLB (*n* = 47), VaD (*n* = 34 for A*β*42, A*β*40; *n* = 33 for A*β*38) and FTD (*n* = 33). Data are presented as mean ± 95% CI; p values are from univariate general linear models controlling for age and sex; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. (F) ROC curves of CSF A*β*42, A*β*42/A*β*40 ratio and A*β*42/A*β*38 ratio for discriminating AD from non‐AD dementias; \*\*\**P* \< 0.001 when comparing to A*β*42 AUC. CSF, cerebrospinal fluid; sMCI, stable mild cognitive impairment; AD, Alzheimer\'s disease; PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies; VaD, vascular dementia; FTD, frontotemporal dementia; ROC, receiver operating characteristic; AUC, area under the curve.](ACN3-3-154-g004){#acn3274-fig-0004}

We used ROC analysis to examine whether the A*β*42/A*β*40 and A*β*42/A*β*38 ratios improve the diagnostic accuracy of AD (the results are summarized in Table [3](#acn3274-tbl-0003){ref-type="table-wrap"}). We found that both ratios performed significantly better than A*β*42 when distinguishing patients with AD from those with PDD/DLB and VaD, as well as from those with non‐AD dementias as a whole group (Table [3](#acn3274-tbl-0003){ref-type="table-wrap"}, Fig. [4](#acn3274-fig-0004){ref-type="fig"}F).

###### 

ROC analysis of CSF A*β*42, A*β*42/A*β*40 ratio and A*β*42/A*β*38 ratio for differentiating AD from other diagnostic groups in cohort‐2

                            AUC, 95% CI                         AUC difference vs. A*β*42 (*P*‐value)
  ------------------------- ----------------------------------- -------------------------------------------------------
  AD vs. sMCI                                                   
  A*β*42                    0.817, 0.743--0.890, *P* \< 0.001   
  A*β*42/A*β*40             0.879, 0.823--0.936, *P* \< 0.001   0.062 (0.028[a](#acn3274-note-0006){ref-type="fn"})
  A*β*42/A*β*38             0.856, 0.790--0.923, *P* \< 0.001   0.039 (0.222)
  AD vs. PDD/DLB                                                
  A*β*42                    0.583, 0.476--0.690, *P* = 0.100    
  A*β*42/A*β*40             0.792, 0.707--0.877, *P* \< 0.001   0.209 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  A*β*42/A*β*38             0.796, 0.710--0.883, *P* \< 0.001   0.213 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  AD vs. VaD                                                    
  A*β*42                    0.698, 0.580--0.816, *P* \< 0.001   
  A*β*42/A*β*40             0.880, 0.814--0.946, *P* \< 0.001   0.182 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  A*β*42/A*β*38             0.860, 0.786--0.935, *P* \< 0.001   0.162 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  AD vs. FTD                                                    
  A*β*42                    0.937, 0.890--0.984, *P* \< 0.001   
  A*β*42/A*β*40             0.946, 0.891--1.000, *P* \< 0.001   0.009 (0.746)
  A*β*42/A*β*38             0.961, 0.912--1.000, *P* \< 0.001   0.024 (0.291)
  AD vs. PDD/DLB and VaD                                        
  A*β*42                    0.630, 0.546--0.715, *P* = 0.002    
  A*β*42/A*β*40             0.828, 0.767--0.890, *P* \< 0.001   0.198 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  A*β*42/A*β*38             0.823, 0.759--886, *P* \< 0.001     0.193 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  AD vs. non‐AD dementias                                       
  A*β*42                    0.720, 0.651--0.788, *P* \< 0.001   
  A*β*42/A*β*40             0.863, 0.813--0.912, *P* \< 0.001   0.143 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})
  A*β*42/A*β*38             0.863, 0.813--0.913, *P* \< 0.001   0.143 (\<0.001[a](#acn3274-note-0006){ref-type="fn"})

The *P*‐values are for comparisons of AUC for the A*β*42/A*β*40 and A*β*42/A*β*38 ratios versus AUC for A*β*42. CSF values derived from the Euroimmun immunoassay. ROC, receiver operating characteristic; CSF, cerebrospinal fluid; AD, Alzheimer\'s disease; AUC, area under the curve; sMCI, stable mild cognitive impairment; PDD, Parkinson\'s disease with dementia; DLB, dementia with Lewy bodies; VaD, vascular dementia; FTD, frontotemporal dementia.

Significantly improved accuracy of the A*β*42/A*β*40 and A*β*42/A*β*38 ratios.

John Wiley & Sons, Ltd

Similar to cohort‐1, all CSF A*β* isoforms, but not the ratios, inversely correlated with the size of the lateral ventricles in cohort‐2 (A*β*38, *P* \< 0.001; A*β*40, *P* \< 0.001; A*β*42, *P* = 0.015).

CSF A*β* isoforms in AD, PD, and PDD/DLB (cohort‐3) {#acn3274-sec-0021}
---------------------------------------------------

To further validate our findings, we analyzed CSF levels of A*β*42, A*β*40, and A*β*38 in an additional cohort consisting of healthy controls and patients with AD, PD, and PDD/DLB. In agreement with the findings in cohort‐2, A*β*40 and A*β*38 levels were lower in the PDD/DLB group compared to the AD group and the separation between AD and PDD/DLB groups was more distinct for the A*β*42/A*β*40 and A*β*42/A*β*38 ratios than for A*β*42 (Fig. S2A--E). Furthermore, compared to A*β*42, the A*β*42/A*β*40, and A*β*42/A*β*38 ratios showed improved accuracy in distinguishing AD from PDD/DLB (*P* = 0.024 and *P* \< 0.001, Fig. S2F).

Correlations between different CSF A*β* isoforms (cohort‐3) {#acn3274-sec-0022}
-----------------------------------------------------------

We studied whether the different CSF A*β* species correlated in healthy elderly, which could indicate that all the three CSF A*β* species are affected similarly by interindividual differences in the underlying A*β* production. The correlations between CSF levels of A*β*42, A*β*40, and A*β*38 were investigated in healthy elderly group in cohort‐3 because it included the largest number of cases. In this group, A*β*42 positively correlated with CSF A*β*40 (Spearman\'s *r* = 0.568, *P* \< 0.001) and CSF A*β*38 (Spearman\'s *r* = 0.484, *P* \< 0.001).

Discussion {#acn3274-sec-0023}
==========

The main finding of this study is that the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios are superior biomarkers of AD pathology compared with A*β*42 alone, which is independent on the applied immunoassay technology. Firstly, using three different immunoassays already used in the field of AD, we showed that the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios predicted cortical accumulation of A*β* fibrils (measured with amyloid PET) with higher accuracy than A*β*42 alone. Secondly, the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios improved differentiation of AD from non‐AD dementias, especially from PDD/DLB and VaD.

Most of the previous studies have found a strong association between CSF A*β*42 and amyloid PET measurements. However, in these studies, 10--20% of healthy individuals and MCI patients show mismatch in CSF A*β*42 and amyloid PET status.[10](#acn3274-bib-0010){ref-type="ref"}, [11](#acn3274-bib-0011){ref-type="ref"}, [20](#acn3274-bib-0020){ref-type="ref"} To the best of our knowledge, this study is first to demonstrate that the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios better predict abnormal cortical amyloid deposition (visualized with PET) compared with A*β*42. The ratios increased the classification performance both for people who were falsely classified as positive (by low CSF A*β*42) and for people who were falsely classified as negative (by high CSF A*β*42). In line with our findings, a positive correlation between the CSF A*β*38/A*β*42 ratio and cortical amyloid load (assessed with Pittsburgh compound B PET) has been reported in cognitively healthy individuals.[27](#acn3274-bib-0027){ref-type="ref"}, [28](#acn3274-bib-0028){ref-type="ref"}

There are several potential explanations for improved concordance between amyloid PET and CSF A*β*, when using the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios instead of A*β*42. It might be that subcortical pathologies not specific to AD cause reduced levels of CSF A*β*42. Some studies have found low CSF A*β*42 levels in multiple system atrophy and multiple sclerosis.[27](#acn3274-bib-0027){ref-type="ref"}, [28](#acn3274-bib-0028){ref-type="ref"} In this study, we show that in patients with mild cognitive complaints, low CSF A*β*42, A*β*40, and A*β*38 were all linked to subcortical injury, including increased white matter lesions and enlarged lateral ventricles. The mechanisms underlying these associations are likely related to dysregulation in APP pathways with a general decline in the production of A*β*.[18](#acn3274-bib-0018){ref-type="ref"} Subcortical injury is accompanied by psychomotor slowing[29](#acn3274-bib-0029){ref-type="ref"}, [30](#acn3274-bib-0030){ref-type="ref"} and preclinical studies suggest that levels of A*β* are modulated by neuronal activity.[31](#acn3274-bib-0031){ref-type="ref"}, [32](#acn3274-bib-0032){ref-type="ref"}, [33](#acn3274-bib-0033){ref-type="ref"} Thus, subcortical injury might result in reduced activity in neuronal networks and thereby diminished production of all A*β* species, including A*β*42. However, in accordance with earlier investigations,[34](#acn3274-bib-0034){ref-type="ref"}, [35](#acn3274-bib-0035){ref-type="ref"} we found that low CSF levels of A*β*42, but not A*β*40 and A*β*38, were associated with more AD‐specific neurodegeneration (i.e., hippocampal atrophy). Altogether, these results indicate that an isolated drop in CSF A*β*42 is more specific for AD‐type pathology, whereas lower CSF levels of all three A*β* isoforms might be associated with subcortical damage in general. In fact, we observed reduced levels of all three A*β* species in PDD/DLB and VaD, disorders that are accompanied by subcortical changes. Further, the A*β*42/A*β*40 and A*β*42/A*β*38 ratios showed 23--36% increase in accuracy compared to A*β*42 alone when differentiating AD from PDD/DLB and VaD (or from non‐AD dementias as a whole group), which is in keeping with previous investigations.[17](#acn3274-bib-0017){ref-type="ref"}, [36](#acn3274-bib-0036){ref-type="ref"}

A second explanation for the improved diagnostic accuracy of the A*β*42/A*β*40 and A*β*42/A*β*38 ratios could be that differences in the overall production and clearance of A*β* probably contribute to interindividual variability in total CSF A*β* levels. This is supported by the present finding that in CSF A*β*42 correlate A*β*38 and A*β*40 even in healthy controls. Consequently, when detecting A*β*42 brain pathology with CSF A*β*42, using ratios to A*β*40 or A*β*38 might correct for interindividual differences in total A*β* levels.[15](#acn3274-bib-0015){ref-type="ref"} Total tau (t‐tau) and phospho‐tau (t‐tau) are biomarkers of neurofibrillary tangles and neurodegeneration[7](#acn3274-bib-0007){ref-type="ref"} and other studies have shown increased diagnostic performance of the A*β*42/t‐tau ratio[37](#acn3274-bib-0037){ref-type="ref"}, [38](#acn3274-bib-0038){ref-type="ref"}, [39](#acn3274-bib-0039){ref-type="ref"} and A*β*42/p‐tau ratio in AD,[40](#acn3274-bib-0040){ref-type="ref"}, [41](#acn3274-bib-0041){ref-type="ref"} but such ratios could be altered due to an isolated increase in CSF tau as seen in, for example brain ischemia or in Creutzfeldt--Jakob disease.[42](#acn3274-bib-0042){ref-type="ref"}, [43](#acn3274-bib-0043){ref-type="ref"}

One potential limitation of this study is the lack of cases with histologically confirmed amyloid pathology. However, supporting the validity of our findings, amyloid PET data show very strong agreement with postmortem plaque measurements.[44](#acn3274-bib-0044){ref-type="ref"}, [45](#acn3274-bib-0045){ref-type="ref"}, [46](#acn3274-bib-0046){ref-type="ref"}

In conclusion, we established that the CSF A*β*42/A*β*40 and A*β*42/A*β*38 ratios increase the level of precision in detecting AD A*β* pathology during both predementia and dementia stages. The introduction of these ratios in clinical practice as well as in clinical trials would be an important step forward to improve the diagnostic work‐up of AD.
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